Orifarm Group A/S Due Diligence
Run due diligence on Orifarm Group A/S: check compliance and get alerts when suppliers or ownership change.
Denmark · owned by HBS Capital ApS (Denmark) · orifarm.com · 33 vendors
Orifarm creates access to great healthcare products by supplying wholesalers, pharmacies, hospitals, and patients with a wide range of pharmaceuticals. The company sources pharmaceuticals at lower costs and provides established household brands to make healthcare more affordable.
Resilience scores
- Digital Sovereignty: 33
- Digital Resilience: 7
- Financial Resilience: 6
Technology vendors
- Omada A/S — Technology — Denmark
- ServiceNow, Inc. — Technology — United States
- Veeam Software Group GmbH — Technology — United States
- and 30 more
Insights
Last updated 2026-09-13 · revision 15
33 direct vendors, 303 subvendors
Direct vendors by controlling owner country (sample)
- Poland: 1
- Luxembourg: 1
- United States: 17
Subvendors by controlling owner country (sample)
- Germany: 7
- Slovenia: 1
- Denmark: 6
Compliance
13 in-scope frameworks identified; showing 3.
EU Pharmacovigilance Regulation — Evidence found
Evidence: https://www.orifarm.com/privacy-policies/, https://www.orifarm.com/about-us/high-product-quality/
Danish Data Protection Act — Evidence found
Evidence: https://www.orifarm.com/privacy-policies/, https://www.orifarm.com/privacy-policies/denmark-privatlivspolitik/
CSRD (source) — No public evidence
Evidence: https://www.orifarm.com/about-us/sustainability-in-orifarm/
Financials
Three-year financials
- 2025: revenue EUR 2.01B, EBIT EUR 96.5M, equity EUR 414M
- 2024: revenue EUR 1.82B, EBIT EUR 69.4M, equity EUR 374M
- 2023: revenue EUR 1.57B, EBIT EUR 76.0M, equity EUR 208M
Financial Resilience Score: 6/10
Orifarm Group A/S demonstrates solid financial resilience underpinned by its position as Europe's largest parallel importer of pharmaceuticals, a diversified three-platform business model (Pharma Trade, Specialty Rx, Consumer Healthcare), and long-term stable family ownership by the Bøgh-Sørensen family. Revenue has grown at approximately 14% CAGR from 2018 to 2024, reaching €1.82B, with EBITDA nearly doubling from 2022 to 2024 (€118.9M in 2024 vs. €61M operating profit in 2022), indicating that the post-Takeda integration is now translating into meaningful profitability improvement. The company operates across 15+ sales markets and 30 purchase markets, providing sourcing arbitrage and geographic diversification within Europe. However, structural weaknesses temper the score. Operating margins remain thin at ~4-6.5%, typical for distribution-heavy pharma but leaving limited buffer against shocks. The debt-funded 2021 Takeda acquisition drove the equity ratio down from ~40% (2019) to 15-16% (2021-2022), materially increasing leverage. Regulatory risk is significant since the parallel-import model depends on EU price differentials that could be squeezed by manufacturer pricing harmonisation or regulatory changes. FX exposure, cost inflation, and post-acquisition integration issues (acknowledged supply issues in 2022, Skælskør site closure completed 2023) add further complexity. Concentration in Europe with minimal US presence limits diversification, and rising CSRD/ESG scrutiny presents compliance costs going forward.
Key strengths: Market leadership as Europe's largest parallel importer of pharmaceuticals, Diversified three-platform model post-Takeda acquisition (110+ brands), Long-term stable family ownership by Bøgh-Sørensen family, Revenue CAGR ~14% from 2018 to 2024, EBITDA nearly doubled from 2022 to 2024 (€118.9M in 2024), Broad geographic footprint: 15 sales markets, 30 purchase markets, 5 production sites, 83.4 million packs sold annually, 4,500+ marketing authorisations, Rising corporate tax contribution (€14.3M in 2024) indicates improving profitability
Risk factors: Regulatory/patent risk from EU free-movement rules and manufacturer pricing harmonisation, Thin operating margins (~4-6.5%) provide limited buffer, Elevated leverage: equity ratio dropped from ~40% to 15-16% post-Takeda acquisition, FX and inflation exposure across multi-country operations, Heavy concentration in Europe with minimal US presence, Post-acquisition integration risk (supply issues in 2022, site closures), ESG/CSRD compliance costs rising from FY2025, Poland production site is a significant Scope 1&2 emissions contributor
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.